Denali Therapeutics Inc. DNLI
Our purpose is to bring the power of biotherapeutics to the whole body, including the brain, by discovering, developing, and delivering medicines for people living with serious diseases.
Historically, the blood-brain barrier has been a major challenge to the development of medicines for diseases of the central nervous system. While the blood-brain barrier protects the brain and is essential for our survival, it also prevents the delivery of medicines to the brain in sufficient quantities to have therapeutic effect. We have invented, developed, and validated a proprietary technology, called the TransportVehicleTM ("TV"), to address the blood-brain barrier challenge and enable a new class of barrier-crossing therapeutics. The TV has a modular design enabling delivery of large molecules, i.e., enzymes, oligonucleotides, and antibodies, to all tissues of the body, including the brain, by crossing the blood-brain barrier after systemic administration. Over the last few decades, large molecule biotherapeutics have enabled medical breakthroughs in treating a wide array of serious diseases, but with very limited success in central nervous system diseases. Now, with the invention and validation of our TV technology, we are leading the field in delivering on the potential of biotherapeutics to transform the lives of individuals with neurodegenerative diseases, lysosomal storage disorders, and other serious diseases.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.5M | $105.1M | $48.7M | $335.6M | $26.3M | $129.1M | $0 | $0 |
| R&D | $418.8M | $396.4M | $423.9M | $358.7M | $265.4M | $212.6M | $193.4M | $143.2M | $74.5M | $75.7M |
| SG&A | $136.6M | $105.4M | $103.4M | $90.5M | $79.1M | $60.3M | $46.5M | $32.3M | $15.7M | $11.7M |
| Total operating expenses | $555.3M | $501.9M | $527.2M | $449.2M | $344.4M | $272.9M | $239.9M | $175.5M | $90.1M | $87.4M |
| Operating income | -$555.3M | -$487.3M | -$196.7M | -$340.7M | -$295.8M | $62.7M | -$213.2M | -$46.4M | -$90.1M | -$87.4M |
| Pre-tax income | -$512.4M | -$422.7M | -$145.2M | -$326.0M | -$290.0M | $72.0M | -$197.3M | -$36.2M | -$88.2M | — |
| Income tax | $102.0K | $68.0K | $30.0K | $21.0K | $575.0K | $823.0K | $351.0K | $0 | $0 | — |
| Net income | -$512.5M | -$422.8M | -$145.2M | -$326.0M | -$290.6M | $71.1M | -$197.6M | -$36.2M | -$88.2M | -$86.7M |
| EPS, basic | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 | 0.65 | -2.07 | -0.39 | — | — |
| EPS, diluted | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 | 0.63 | -2.07 | -0.39 | -5.89 | -13.49 |
| Shares, diluted (wtd. avg.) | 172.6M | 164.5M | 137.4M | 125.5M | 121.5M | 112.7M | 95.6M | 92.6M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $205.3M | $175.0M | $128.7M | $219.5M | $295.0M | $508.6M | $80.9M | $78.6M | $218.9M | $40.4M |
| Short-term investments | $662.6M | $657.4M | $907.4M | $1.12B | $571.9M | $962.6M | $335.9M | $387.2M | $187.9M | — |
| Total current assets | $900.7M | $864.4M | $1.06B | $1.37B | $897.2M | $1.50B | $430.0M | $480.8M | $409.6M | — |
| Property, plant and equipment | $52.4M | $55.2M | $45.6M | $44.1M | $38.9M | $40.8M | $46.7M | $25.2M | $14.9M | — |
| Total assets | $1.14B | $1.37B | $1.15B | $1.46B | $1.40B | $1.60B | $553.2M | $662.0M | $486.7M | — |
| Accounts payable | $3.3M | $11.1M | $9.5M | $2.8M | $4.8M | $1.1M | $2.6M | $1.9M | $2.7M | — |
| Total current liabilities | $98.4M | $102.2M | $78.0M | $363.9M | $378.2M | $71.7M | $45.3M | $32.8M | $14.2M | — |
| Total liabilities | $131.1M | $144.5M | $123.0M | $417.8M | $441.9M | $453.7M | $158.3M | $115.1M | $20.9M | — |
| Retained earnings | -$2.05B | -$1.54B | -$1.12B | -$971.0M | -$645.0M | -$354.4M | -$425.6M | -$227.9M | -$191.7M | — |
| Total equity | $1.01B | $1.23B | $1.03B | $1.04B | $962.3M | $1.15B | $394.9M | $546.8M | $465.8M | -$94.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$412.6M | -$347.7M | -$358.0M | -$244.7M | -$211.4M | $416.2M | -$151.6M | $50.1M | -$76.6M | -$71.9M |
| Depreciation and amortisation | $11.2M | $7.8M | $16.7M | $10.4M | $8.6M | $8.5M | $8.0M | $7.4M | $3.1M | $1.5M |
| Stock-based compensation | $99.6M | $102.9M | $108.1M | $99.8M | $85.2M | $50.4M | $38.4M | $18.8M | $4.4M | $3.0M |
| Capital expenditure | $9.5M | $15.9M | $12.9M | $17.8M | $8.5M | $3.1M | $17.9M | $3.4M | $2.9M | $6.1M |
| Investing cash flow | $255.3M | -$88.8M | $249.3M | -$141.4M | -$21.6M | -$623.2M | $147.7M | -$287.4M | -$41.2M | -$219.0M |
| Financing cash flow | $189.2M | $484.3M | $17.8M | $310.7M | $19.3M | $634.7M | $6.2M | $97.0M | $296.3M | $300.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001714899-26-000054.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $129.1M | $26.3M | $335.6M | $48.7M | $105.1M | $330.5M | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$86.7M | -$88.2M | -$36.2M | -$197.6M | $71.1M | -$290.6M | -$326.0M | -$145.2M | -$422.8M | -$512.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |